InfuSystem Holdings, Inc Revenue Disclosure
| Years Ended December 31, | |||||||||||||||||||||||
| 2025 | 2024 | ||||||||||||||||||||||
Total Net Revenues | % of Total Net Revenues | Total Net Revenues | % of Total Net Revenues | ||||||||||||||||||||
Patient Services revenue recognized at a point in time: | |||||||||||||||||||||||
Direct products | $ | 2,591 | 1.8 | % | $ | 2,706 | 2.0 | % | |||||||||||||||
Third-Party Payer products | 17,750 | 12.4 | % | 15,023 | 11.1 | % | |||||||||||||||||
Patient Services revenue recognized over time: | |||||||||||||||||||||||
Direct rental services | 7,755 | 5.4 | % | 7,683 | 5.7 | % | |||||||||||||||||
Third-Party Payer rental services | 50,091 | 34.9 | % | 47,394 | 35.1 | % | |||||||||||||||||
Total Patient Services accounted for under ASC 606 | 78,187 | 54.5 | % | 72,806 | 53.9 | % | |||||||||||||||||
Device Solutions revenue recognized at a point in time: | |||||||||||||||||||||||
Products | 17,274 | 12.0 | % | 16,552 | 12.3 | % | |||||||||||||||||
Services | 11,829 | 8.2 | % | 8,861 | 6.6 | % | |||||||||||||||||
Device Solutions revenue recognized over time: | |||||||||||||||||||||||
| Services | 5,790 | 4.0 | % | 8,082 | 6.0 | % | |||||||||||||||||
Total Device Solutions accounted for under ASC 606 | 34,893 | 24.3 | % | 33,495 | 24.9 | % | |||||||||||||||||
Total Revenue Accounted for under ASC 606 | 113,080 | 78.8 | % | 106,301 | 78.8 | % | |||||||||||||||||
Patient Services Lease Revenue | 8,345 | 5.8 | % | 7,572 | 5.6 | % | |||||||||||||||||
Device Solutions Lease Revenue | 22,011 | 15.3 | % | 20,988 | 15.6 | % | |||||||||||||||||
Total Revenue accounted for under ASC 842 | 30,356 | 21.2 | % | 28,560 | 21.2 | % | |||||||||||||||||
Total Net Revenue | $ | 143,436 | 100.0 | % | $ | 134,861 | 100.0 | % | |||||||||||||||
| 2025 | 2024 | Change in 2025 | |||||||||||||||
| Accounts receivable, net | $ | 22,901 | $ | 21,155 | $ | 1,746 | |||||||||||
| Contract assets | $ | 1,244 | $ | 570 | $ | 674 | |||||||||||
| Contract liabilities | $ | 109 | $ | — | $ | 109 | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 27, 2026 | Showing above |
| 2024 | Mar 11, 2025 | |
| 2023 | Apr 10, 2024 | |
| 2022 | Mar 16, 2023 | |
| 2021 | Mar 15, 2022 | |
| 2020 | Mar 22, 2021 | |
| 2019 | Mar 30, 2020 | |
| 2018 | Mar 22, 2019 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.